Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 | |
| SCHEMBL29367804 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 | |
| SCHEMBL23705539 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 | |
| Carbimide SCHEMBL10800076 | 0.95 | SMN1; SMN2 (0.90) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 | |
| 1,2-Dichloroethane SCHEMBL28697158 | 0.95 | SMN1; SMN2 (0.90) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 | |
| SCHEMBL8608444 | 0.93 | SMN1; SMN2 (0.86) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 | |
| Dimethylformamide SCHEMBL7714545 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 | |
| SCHEMBL8063974 | 0.91 | SMN1; SMN2 (0.82) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 | |
| SCHEMBL8608446 | 0.91 | SMN1; SMN2 (0.82) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 | |
| SCHEMBL9188247 | 0.90 | SMN1; SMN2 (0.82) | SMN1; SMN2LMNAMEN1KMT2AP2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486771-A | Thiocarbonate-based hydrogen sulfide donor, and preparation method and application thereof | 上海交通大学 | 2024-02-02 | — | — | CN | claimed |
| WO-2019200764-A1 | IMPROVED CELLULOSE AND PREPARATION METHOD AND APPLICATION THEREFOR | 东莞理工学院 | 2019-10-24 | — | — | WO | claimed |
| US-20240209001-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p. A. (IT) | 2024-06-27 | — | — | US | disclosed |
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | IMMUNOGEN, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoirens Serviece (FR) | 2024-06-06 | — | — | US | disclosed |
| EP-4376886-A2 | METHODS OF TREATING CANCER | Foghorn Therapeutics Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-107108507-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11981687-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| CN-110637011-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-118043053-A | Methods of treating cancer | 福宏治疗公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-110637015-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-1997006138-A1 | 4-MERCAPTOPYRROLIDINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1997-02-20 | — | — | WO | disclosed |
| EP-0694036-A1 | HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 1996-01-31 | — | — | EP | disclosed |
| WO-1994024140-A1 | HYDROXAMIC ACID DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-10-27 | — | — | WO | disclosed |
| US-5324786-A | Process for preparation of a solid phase system | ORPEGEN MEDIZINISCHE-MOLEKULAR BIOLOGISCHE FORSCHUNGSGESELLSCHAFT MBH (DE) | 1994-06-28 | — | — | US | disclosed |
| US-5214195-A | ALLYL ESTERS AND THE USE THEREOF FOR THE BUILD-UP OF SOLID PHASE SYSTEMS FOR SOLID PHASE REACTIONS | ORPEGEN MEDIZINISCH-MOLEKULAR BIOLOGISCHE FORSCHUNGSGESELLSCHAFT MBH (DE) | 1993-05-25 | — | — | US | disclosed |
| EP-0415331-A2 | Allyl esters and their application to the construction of solid phase systems for solid phase reactions | Orpegen Medizinisch-Molekularbiologische Forschungsgesellschaft m.b.H. (DE) | 1991-03-06 | — | — | EP | disclosed |
| EP-0298820-A1 | Peptide derivatives and their therapeutic application | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-01-11 | — | — | EP | disclosed |
| US-4066831-A | ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1978-01-03 | — | — | US | disclosed |
| US-4012383-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981687-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | SMN1; SMN2 2230/4885LMNA 945/4885MEN1 2163/4885 |
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MKI67, GABBR1, GABBR2 | SMN1; SMN2 3393/4885LMNA 2428/4885MEN1 1230/4885 |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | SMN1; SMN2 2309/4885LMNA 645/4885MEN1 3679/4885 |
| US-20240209001-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK3, JAK1 | SMN1; SMN2 4462/4885LMNA 4155/4885MEN1 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.